EGFR and adenocarcinoma: For example, in our cohort, canonical oncodriver mutations were identified in three of the six tumors with an adenocarcinoma component (SOS1 in Pa34, EGFR/PIK3CA in Pa35, and KRAS/PIK3CA in Pa37) compared to pure LUADs, the majority of which harbor driver mutations.